ArticleBMC gastroenterology2026
Combined TIPS and TACE for patients with hepatocellular carcinoma and variceal bleeding secondary to portal vein tumor thrombus.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe study aimed to assess the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) patients who have portal vein tumor thrombus (PVTT) and variceal bleeding secondary to portal hypertension.
methodsThis retrospective study analysed 39 patients with HCC and PVTT who experienced variceal bleeding and were treated with TIPS and TACE from June 2018 to April 2025. The evaluated outcomes included the technical success, clinical success and overall survival (OS).
resultsThe technical success rate was 100%. Variceal bleeding was successfully controlled in all patients. Among these patients, 13 (33.3%) developed overt hepatic encephalopathy (HE) after TIPS. There were no other significant procedure-related complications. The recurrence rate of variceal bleeding was 25.6% at 1 year. After TACE, all patients exhibited a reduction in tumor size, with 26 (66.7%) patients achieving partial response (PR) and 13 (33.3%) patients achieving stable disease (SD). The median OS was 12.2 (95% CI: 10.9-13.5) months and OS rates were 89.7% at 1 month, 76.9% at 3 months, 56.4% at 6 months, and 46.2% at 12 months.
conclusionTIPS combined with TACE appears to be safe and effective for patients who had HCC and PVTT complicated with variceal bleeding secondary to portal hypertension. CLINICAL SIGNIFICANCE: This study found that the combination of TIPS and TACE is a safe and effective treatment for patients with HCC and PVTT. The treatment successfully stopped the bleeding in all patients, helped shrink the tumors in most, and improved overall survival. This approach not only manages the life-threatening bleeding but also allows for further treatment of the liver cancer itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.